HC-5404-FU
- Generic Name
- HC-5404-FU
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
Phase 1
Completed
- Conditions
- Metastatic Breast CancerRenal Cell CarcinomaOther Solid TumorsSmall-cell Lung CancerGastric Cancer
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04834778
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸HealthPartners Cancer Care Center, Saint Paul, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath